Polydatin

Polydatin is a stilbene glycoside naturally occurring in Japanese knotweed (Polygonum cuspidatum) and grape skin, functioning as a glycosylated precursor to resveratrol. It exerts antioxidant and anti-inflammatory effects primarily by scavenging reactive oxygen species and modulating NF-κB signaling pathways.

Origin & History

Polydatin is a stilbenoid glycoside (the 3-O-β-D-glucopyranoside of resveratrol) primarily extracted from the roots and rhizomes of Fallopia japonica (Japanese knotweed), as well as from grape skins, red/white wines, peanuts, berries, hop cones, and cocoa products. Production methods include direct extraction from plant material or biotransformation via microbial glucosylation of resveratrol using bacteria like Bacillus cereus.

Historical & Cultural Context

Fallopia japonica (known as Huzhang in traditional Chinese medicine and Itadori in Japanese medicine) has been used historically for analgesic, anti-pyretic, anti-inflammatory, anti-infection, jaundice, skin burns, and hyperlipemia treatments. The roots and rhizomes have served as the primary source in East Asian traditional medicine systems, predating modern isolation of polydatin.

Health Benefits

• Anti-inflammatory effects demonstrated in preclinical models (evidence quality: preliminary - in vitro/animal studies only)
• Antioxidant activity showing enhanced effects compared to resveratrol (evidence quality: preliminary - mechanistic studies)
• Anti-tumor properties including cytotoxic effects on colorectal cancer cells via cell cycle arrest and apoptosis (evidence quality: preliminary - in vitro studies)
• Immunoregulatory effects observed in preclinical research (evidence quality: preliminary - no human trials cited)
• Potential cardiovascular support through oxidative stress modulation (evidence quality: preliminary - mechanistic data only)

How It Works

Polydatin inhibits NF-κB activation, thereby suppressing downstream pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. It activates the Nrf2/HO-1 antioxidant pathway, upregulating heme oxygenase-1 and superoxide dismutase to neutralize reactive oxygen species. Additionally, polydatin modulates SIRT1 and AMPK signaling, influencing cellular energy metabolism and apoptotic pathways via caspase-3 and Bcl-2 family proteins.

Scientific Research

The research dossier indicates that search results lack specific details on human clinical trials, RCTs, or meta-analyses for polydatin, with no PubMed PMIDs provided for human studies. Current evidence is limited to preclinical studies demonstrating anti-inflammatory, antioxidant, and anti-tumor activities in cell and animal models.

Clinical Summary

The majority of polydatin research consists of in vitro cell studies and rodent models, with limited human clinical data currently available. A small number of pilot human trials have examined polydatin in the context of metabolic disorders and inflammation, including one study of roughly 30 participants showing modest reductions in oxidative stress biomarkers such as malondialdehyde. Preclinical studies consistently demonstrate cytotoxic activity against cancer cell lines including HeLa and MCF-7 at concentrations of 50–200 μM, though these findings have not been replicated in clinical trials. Evidence quality remains preliminary, and no large-scale randomized controlled trials have established efficacy or optimal dosing in humans.

Nutritional Profile

Polydatin (piceid) is a stilbenoid glucoside compound (C₂₀H₂₂O₈, MW 390.38 g/mol) and the primary natural precursor/glycosylated form of resveratrol. It is not a macronutrient source and has no caloric, protein, fat, or fiber contribution at typical supplement or dietary doses. Key biochemical characteristics: • Structure: Resveratrol-3-O-β-mono-D-glucoside; a single glucose moiety attached at the 3-position of resveratrol, conferring significantly improved water solubility (~30-fold greater than resveratrol) and enhanced stability against enzymatic oxidation and UV-light degradation. • Natural concentrations: Found in Polygonum cuspidatum (Japanese knotweed) root at approximately 0.5–3.0% dry weight (primary commercial source); also present in red grapes (skin: ~0.5–10 mg/kg fresh weight), red wine (~0.5–15 mg/L), peanuts (~0.01–0.5 mg/kg), and various berries in trace amounts. • Bioavailability: Substantially superior oral bioavailability compared to free resveratrol due to active absorption via sodium-dependent glucose cotransporters (SGLT1) in the intestinal epithelium, rather than passive diffusion alone. Studies in animal models suggest ~3–4× higher plasma concentrations (AUC) relative to equimolar doses of resveratrol. The glucose moiety protects against rapid Phase II conjugation (glucuronidation/sulfation) in the intestinal wall and liver, though polydatin is ultimately hydrolyzed to resveratrol by gut microbiota β-glucosidases and enterocyte enzymes. • Key bioactive properties: Potent free radical scavenging (DPPH IC₅₀ ~15–25 µM); inhibition of NF-κB signaling; activation of SIRT1 and AMPK pathways; modulation of Nrf2/ARE antioxidant response element. Typical experimental concentrations range from 10–200 µM in vitro and 25–200 mg/kg body weight in animal models. • Supplement doses: Commonly available at 50–500 mg per capsule; no established RDA or official dietary reference intake. • Micronutrient content: No significant vitamins or minerals are inherent to the isolated compound. When consumed via whole food sources (e.g., grape skin, Japanese knotweed extract), co-occurring compounds include emodin, physcion, other stilbenes (resveratrol, resveratroloside), catechins, and trace minerals dependent on plant matrix.

Preparation & Dosage

No clinically studied dosage ranges, forms, or standardization details are available from human trials. Industrial-scale extraction from Polygonum cuspidatum suggests potential for standardized root extracts, but no quantitative dosing guidelines have been established through clinical research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Resveratrol, Quercetin, Green Tea Extract, Curcumin, Grape Seed Extract

Safety & Interactions

Polydatin is generally considered well-tolerated at doses used in preliminary human studies, typically ranging from 40 to 120 mg per day, with no severe adverse events reported in short-term use. Due to its structural similarity to resveratrol, it may inhibit CYP450 enzymes (particularly CYP3A4 and CYP2C9), potentially increasing plasma levels of anticoagulants like warfarin and certain statins. Polydatin has demonstrated estrogenic activity in preclinical models, making it potentially contraindicated for individuals with hormone-sensitive conditions such as estrogen receptor-positive breast cancer. Pregnant and breastfeeding women should avoid supplementation due to insufficient safety data in these populations.